| Study | Bronchiectasis | Healthy controls | PCD | |||
| Subjects n | nNO nL·min−1 | Subjects n | nNO nL·min−1 | Subjects n | nNO nL·min−1 | |
| Narang et al. [7], 2002 | 21 | 133.4 (20–513.3) | 53 | 179 (99.5–359.3) | 31 | 15.1 (0.8–230) |
| Horvath et al. [8], 2003 | 31 | 170 (77.5–250) | 37 | 165.8 (80.5–335.8) | 14 | 13.6 (1.3–67.3) |
| Wodehouse et al. [9], 2003 | 20 | 220.1±49.1 | 16 | 227.7±43.7 | 42 | 19.7±11.0 |
| Wodehouse et al. [9], 2003# | 12 | 193.2±39.0 | ||||
| Shoemark et al. [23], 2009 | 20 | 223±127.8 | 20 | 159.8±133.5 | 20 | 12.3±8.6 |
| Moreno Galdó et al. [24], 2010 | 8 | 90.3±39.2 | 37 | 224.5±37.1 | 9 | 22.0±29.9 |
| Mateos-Corral et al. [26], 2011 | 6 | 376.2±346.4 | 10 | 366.5±131.7 | 150 | 17.9±13.7 |
| Harrison et al. [28], 2012¶ | 4 | 75.3±81.9 | 5 | 125.7±22.8 | 12 | 15.6±11.6 |
Data are presented as median (range) or mean±sd, unless otherwise stated. nNO: nasal nitric oxide; PCD: primary ciliary dyskinesia. #: Young’s syndrome; ¶: measured by portable NIOX MINO analyser.